Evidence map›Paper›PMID 39279937›Full record

ArticleJournal of gastrointestinal oncology2024

Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.

Gareth Pollin, Gwen A Lomberk, Angela J Mathison, Michael T Zimmermann, Raul Urrutia

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Gareth PollinThe RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0002-2787-6673
Gwen A LomberkThe RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0001-5463-789X
Angela J MathisonThe RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0002-6763-2710
Michael T ZimmermannThe RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0001-7073-0525
Raul UrrutiaThe RASopathies Program, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID https://orcid.org/0000-0002-1640-6780

Funding

ZINC FINGER GENES AND PANCREATIC CELL GROWTHR01DK052913 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN, URRUTIA, RAUL A. · 1998 to 2023
$7.0M
Targeting Epigenomic Regulators at the Replication Fork in PDACR01CA247898 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN · 2021 to 2025
$2.3M
NCI NIH HHS R01 CA247898NIDDK NIH HHS R01 DK052913
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

inhibitorsMRTX1133mutant KRASPancreatic ductal adenocarcinoma (PDAC)RASopathy

Identifiers

PMID39279937
PMCPMC11399826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.